Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432793 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction (DDI) Study for TD-9855
A Phase 1 study of Drug-Drug Interaction (DDI), sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT03432793 is a Phase 1 study of Drug-Drug Interaction (DDI) that has completed, run by Theravance Biopharma. The registered enrollment target is 41 participants, roughly in line with the 43-participant average among 3 other Drug-Drug Interaction (DDI) trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03432793, a Phase 1 study of Drug-Drug Interaction (DDI), has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
Conditions Studied
Interventions
- DRUG Itraconazole
- DRUG Caffeine
- DRUG Fluvoxamine
- DRUG TD-9855
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2018-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432793
The ClinicalTrials.gov registry entry for NCT03432793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 43-participant average among 3 other Drug-Drug Interaction (DDI) trials with a reported enrollment target. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug-Drug Interaction (DDI) appearing as the primary indexed condition, and to 4 interventions - of which Itraconazole is the first listed.
NCT03432793 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT03432793 about?
NCT03432793 is a clinical study titled "Drug-Drug Interaction (DDI) Study for TD-9855". This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
What is the current status of trial NCT03432793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2018-02-28. Estimated completion is 2018-04-21.
What conditions does trial NCT03432793 study?
This clinical trial studies the following conditions: Drug-Drug Interaction (DDI).
What interventions are being tested in trial NCT03432793?
The interventions under investigation include: Itraconazole (DRUG), Caffeine (DRUG), Fluvoxamine (DRUG), TD-9855 (DRUG).
Who is sponsoring clinical trial NCT03432793?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03432793 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug-Drug Interaction (DDI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
ACTIVE NOT RECRUITING · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.